Company profile
Gilead Sciences
Diversified biopharma
Share price · GILD
$143.44+13.77 (+10.62%) 3M
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Unadjusted for historical splits · Data via Databento
Assets
(16 total)
16Total Assets
7Approved
6Phase 3 / Filed
3Phase 1–2 / Early
7Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
Ambrisentan(Letairis) | Approved | Endothelin A receptorSmall molecule | Hypertension |
Bictegravir(Biktarvy) | Approved | HIV integraseSmall molecule | HIVAtherosclerotic Cardiovascular Disease |
Elvitegravir(Stribild / Genvoya (component)) | Approved | HIV integraseSmall molecule | HIV |
| Approved | HIV reverse transcriptaseSmall molecule | HIVAtherosclerotic Cardiovascular Disease | |
Lenacapavir(Sunlenca / Yeztugo) | Approved | HIV capsidSmall molecule | HIV |
| Approved | TROP2Antibody–drug conjugate | Non-Small Cell Lung CancerHR+/HER2- Breast Cancer HR+/HER2- Metastatic Breast Cancer | |
Tenofovir alafenamide/emtricitabine(Descovy) | Approved | HIV reverse transcriptaseSmall molecule | HIV |
| Phase 3 | HIV envelopeMonoclonal antibody | HIV | |
| Phase 3 | BCMACell therapy | Multiple Myeloma | |
filgotinib(Jyseleca) | Phase 3 | JAK · JAK1Small molecule | Rheumatoid Arthritis |
| Phase 3 | HIV envelopeMonoclonal antibody | HIV | |
| Phase 3 | Toll-like receptor 7 (TLR7) (agonist)Small molecule | HIV | |
| Phase 3 | HIV envelopeMonoclonal antibody | HIV | |
| Phase 2 | HIV envelopeMonoclonal antibody | HIV | |
| Phase 2 | HIV antigensVaccine | HIV |
Upcoming events
Research
Sign in to access ResearchUnlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Research
Sign in to access ResearchUnlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.
Insider transactions
Research
Sign in to access ResearchUnlock insider transactions
Research includes SEC Form 4 insider transactions — filed buys, sells, awards and exercises linked to the underlying filings.
Institutional holders
Research
Sign in to access ResearchUnlock institutional holders
Research includes quarterly SEC 13F institutional ownership — top holders, aggregate positions and quarter-over-quarter context.